View More View Less
  • 1 Semmelweis Egyetem, Budapest, Üllői út 26., 1085
Open access

Absztrakt:

A különböző szerveket érintő betegségek gyógyításában szisztémásan alkalmazott gyógyszerek szemészeti mellékhatásai lehetnek tünetmentes elváltozások, azonban látást veszélyeztető kórképek is, mint a toxikus retinopathia vagy az opticus neuropathia. A szemészeti szűrővizsgálatok során a mellékhatások korai felismerésével a további progresszió és a maradandó látáskárosodás az esetek többségében megelőzhető. Összefoglaló közleményünkben a klinikai gyakorlatban széles körben használt gyógyszerek leggyakoribb és legjelentősebb szemészeti mellékhatásait ismertetjük. Célunk a gyógyszereket felíró orvosok tájékoztatása a terápia lehetséges szemészeti szövődményeiről, a szemészeti vizsgálatok fontosságáról és rendszerességéről. Orv Hetil. 2020; 161(23): 951–961.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Mäntyjärvi M, Tuppurainen K, Ikäheimo K. Ocular side effects of amiodarone. Surv Ophthalmol. 1998; 42: 360–366.

  • 2

    Mindel JS, Anderson J, Johnson G, et al. Absence of bilateral vision loss from amiodarone: a randomized trial. Am Heart J. 2007; 153: 837–842.

  • 3

    Gurwood AS. Optometric clinical practice recommendations for monitoring ocular toxicity of selected medications. American Optometric Association. Available from: http://www.aoa.org/Documents/optometrists/QI/optometric-clinical-practice-recommendations-for-monitoring-ocular-toxicity-of-selected-medications.pdf [accessed: May 13, 2015].

  • 4

    Godel V, Feiler-Ofry V, Stein R. Systemic steroids and ocular fluid dynamics. I. Analysis of the sample as a whole: Influence of dosage and duration of therapy. II. Systemic versus topical steroids. Acta Ophthalmol (Copenh). 1972; 50: 655–663, 664–676.

  • 5

    James ER. The etiology of steroid cataract. J Ocul Pharmacol Ther. 2007; 23: 403–420.

  • 6

    Peponis V, Kyttaris VC, Chalkiadakis SE, et al. Ocular side effects of anti-rheumatic medications: what a rheumatologist should know. Lupus 2010; 19: 675–682.

  • 7

    Csorba A, Soproni A, Maneschg O, et al. Application of corticosteroid eye drops for allergic eye diseases in children. [A kortikoszteroidtartalmú szemcseppek alkalmazása gyermekkori allergiás szembetegségek kezelésében.] Orv Hetil. 2019; 160: 329–337. [Hungarian]

  • 8

    Daruich A, Matet A, Dirani A. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015; 48: 82–118.

  • 9

    Han JM, Hwang JM, Kim JS, et al. Changes in choroidal thickness after systemic administration of high-dose corticosteroids: a pilot study. Invest Ophthalmol Vis Sci. 2014; 55: 440–445.

  • 10

    Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014; 132: 1453–1460.

  • 11

    Marmor MF, Kellner U, Lai TY, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology 2016; 123: 1386–1394.

  • 12

    Alwitry A, Gardner I. Tamoxifen maculopathy. Arch Ophthalmol. 2002; 120: 1402.

  • 13

    Bourla DH, Sarraf D, Schwartz SD. Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy. Am J Ophthalmol. 2007; 144: 126–128.

  • 14

    Gualino V, Cohen SY, Delyfer MN, et al. Optical coherence tomography findings in tamoxifen retinopathy. Am J Ophthalmol. 2005; 140: 757–758.

  • 15

    Vinding T, Nielsen NV. Retinopathy caused by treatment with tamoxifen in low dosage. Acta Ophthalmol (Copenh). 1983; 61: 45–50.

  • 16

    Besch D, Zrenner E, Sadowski B. Reversibility of Tamoxifen® retinopathy – a ten-year follow-up. Neuro-Ophthalmology 2009; 32: 214–221.

  • 17

    Méndez-Martínez S, Calvo P, Ruiz-Moreno O, et al. Ocular adverse events associated with MEK inhibitors. Retina 2019; 39: 1435–1450.

  • 18

    Schulman JA, Liang C, Kooragayala LM, et al. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology 2003; 110: 437–442.

  • 19

    Okuse C, Yotsuyanagi H, Nagase Y, et al. Risk factors for retinopathy associated with interferon α-2b and ribavirin combination therapy in patients with chronic hepatitis C. World J Gastroenterol. 2006; 12: 3756–3759.

  • 20

    Medhat E, Esmat G, Hamza E, et al. Ophthalmological side effects of interferon therapy of chronic hepatitis C. Hepatobiliary Surg Nutr. 2016; 5: 209–216.

  • 21

    Abd El-Badie Mohamed M, Abd-El Azeem Eed K. Retinopathy associated with interferon therapy in patients with hepatitis C virus. Clin Ophthalmol. 2012; 6: 1341–1345.

  • 22

    Fraunfelder FW, Fraunfelder FT. Interferon alfa-associated anterior ischemic optic neuropathy. Ophthalmology 2011; 118: 408– 411.e2.

  • 23

    Koul PA. Ocular toxicity with ethambutol therapy: timely recaution. Lung India 2015; 32: 1–3.

  • 24

    Chai SJ, Foroozan R. Decreased retinal nerve fibre layer thickness detected by optical coherence tomography in patients with ethambutol-induced optic neuropathy. Br J Ophthalmol. 2007; 91: 895–897.

  • 25

    Chan RY, Kwok AK. Ocular toxicity of ethambutol. Hong Kong Med J. 2006; 12: 56–60.

  • 26

    Gümüş A, Öner V. Follow up of retinal nerve fiber layer thickness with optic coherence tomography in patients receiving anti-tubercular treatment may reveal early optic neuropathy. Cutan Ocul Toxicol. 2015; 34: 212–216.

  • 27

    Diederen RM, La Heij EC, Markerink-van Ittersum M, et al. Selective blockade of phosphodiesterase types 2, 5 and 9 results in cyclic 3’5’ guanosine monophosphate accumulation in retinal pigment epithelium cells. Br J Ophthalmol. 2007; 91: 379–384.

  • 28

    Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998; 338: 1397–1404.

  • 29

    McGwin G Jr, Vaphiades MS, Hall TA, et al. Non-arteritic anterior ischaemic optic neuropathy and the treatment of erectile dysfunction. Br J Ophthalmol. 2006; 90: 154–157. [This article has been retracted. Retraction: Br J Ophthalmol. 2011; 95(4): 595.]

  • 30

    Malek N, Lebuisson DA. Adverse ocular reactions to oral contraceptive use. [Le point sur les complications oculaires de la contraception orale.] Contracept Fertil Sex (Paris) 1992; 20: 441–444. [French]

  • 31

    Peragallo Urrutia R, Coeytaux RR, et al. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol. 2013; 122: 380–389.

  • 32

    Fraunfelder FW, Fraunfelder FT, Keates EU. Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology 2004; 111: 109–111.

  • 33

    P. Watts. Ocular side effects of topiramate – frequently asked questions. The Royal College of Ophthalmologists, Paediatric Sub-Committee, London, 2010. Available from: https://www.rcophth.ac.uk/wp-content/uploads/2014/12/2010_PROF_124_FAQ-Topiramate.pdf [accessed: January 6, 2020].

  • 34

    Krauss GL. Evaluating risk for vigabatrin treatment. Epilepsy Curr. 2009; 9: 125–129.

  • 35

    Hardus P, Verduin WM, Postma G, et al. Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin. Br J Ophthalmol. 2000; 84: 788–790.

  • 36

    Torzsa P, Szeifert L, Dunai K, et al. Diagnosis and therapy of depression in primary care. [A depresszió diagnosztikája és kezelése a családorvosi gyakorlatban.] Orv Hetil. 2009; 150: 1684–1693. [Hungarian]

  • 37

    Acan D, Kurtgoz P. Influence of selective serotonin reuptake inhibitors on ocular surface. Clin Exp Optom. 2017; 100: 83–86.

  • 38

    Ah-Kee EY, Egong E, Shafi A, et al. A review of drug-induced acute angle closure glaucoma for non-ophthalmologists. Qatar Med J. 2015; 2015: 6.

  • 39

    Neudorfer M, Goldshtein I, Shamai-Lubovitz O, et al. Ocular adverse effects of systemic treatment with isotretinoin. Arch Dermatol. 2012; 148: 803–808.

  • 40

    Halpagi P, Grigg J, Klistorner A, et al. Night blindness following low-dose isotretinoin. J Eur Acad Dermatol Venereol. 2008; 22: 893–894.

  • 41

    Mollan SP, Woodcock M, Siddiqi R, et al. Does use of isotretinoin rule out a career in flying? Br J Ophthalmol. 2006; 90: 957–959.

  • 42

    Tintle SJ, Harper JC, Webster GF, et al. Safe use of therapeutic-dose oral isotretinoin in patients with a history of pseudotumor cerebri. JAMA Dermatol. 2016; 152: 582–584.

  • 43

    Romics I. Treatment of benign prostate hyperplasia. [A benignus prostatahyperplasia kezelése.] Orv Hetil. 2010; 151: 506–508. [Hungarian]

  • 44

    Kaczmarek IA, Prost ME, Wasyluk J. Clinical risk factors associated with intraoperative floppy iris syndrome: a prospective study. Int Ophthalmol. 2019; 39: 541–549.

  • 45

    Palea S, Chang DF, Rekik M, et al. Comparative effect of alfuzosin and tamsulosin on the contractile response of isolated rabbit prostatic and iris dilator smooth muscles. Possible model for intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2008; 34: 489–496.

  • 46

    Chang DF, Osher RH, Wang L, et al. A prospective multicenter evaluation of cataract surgery in patients taking tamsulosin (Flomax). Ophthalmology 2007; 114: 957–964.

  • 47

    Kiire CA, Mukherjee R, Ruparelia N, et al. Managing antiplatelet and anticoagulant drugs in patients undergoing elective ophthalmic surgery. Br J Ophthalmol. 2014; 98: 1320–1324.